Immunovia AB (publ) is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Immunovia’s shares are listed on Nasdaq Stockholm.
Vinge has advised Smart Eye Aktiebolag (First North Growth Market) in connection with its fully secured rights issue which provided Smart Eye with MSEK 324 before transaction costs. The issue was fully subscribed and no guarantee commitments had to be utilised.
Vinge advises Biotage AB (publ) (“Biotage”) in connection with its acquisition of Astrea Bioseparations (“Astrea”), a high-growth chromatography solutions provider from Gamma Biosciences (“Gamma”), a life sciences tools platform created and controlled by KKR.
Vinge has advised Neobo Fastigheter AB (publ) (”Neobo”) in connection with the listing of Neobo’s shares on Nasdaq First North Premier. The company description was published on 6 February 2023 and the first day of trading on Nasdaq First North Premier was on 10 February 2023.
Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a directed share issue whereby the company raised proceeds of SEK 210 million before issue costs.
Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) in connection with the distribution of the shares in Neobo Fastigheter AB (publ) (”Neobo”) to the A and B shareholders in SBB. The resolution on the distribution was adopted at the Extraordinary General Meeting of SBB on 21 December 2022 and the distribution was carried out on 30 December 2022.
Vinge has advised Acrinova AB (publ) (“Acrinova” or the “Company”) in connection with the Company’s uplisting to Nasdaq Stockholm. The prospectus was published on 9 December 2022 and trading on Nasdaq Stockholm commenced on 16 December 2022.
Vinge has advised Hansa Biopharma in connection with a directed share issue through which the company raises proceeds of SEK 415.9 million before transaction costs.
Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore Pharma receives gross proceeds of SEK 200 million.
Vinge has advised BICO Group AB in connection with a directed share issue to Sartorius AG, adding a total amount of MSEK 487 to BICO. The subscription price of SEK 76 was equivalent to a premium of 2.7 per cent compared with a 3-day VWAP. In connection with the share issue, BICO and Sartorius have entered into an extensive co-operation agreement concerning technical, sales and marketing issues.
Vinge has advised LumenRadio AB (publ) (“LumenRadio”) in connection with its listing on Nasdaq First North Growth Market. The prospectus was published on 28 November 2022 and the first day of trading occurred on 8 December 2022.
Tidnings AB Marieberg, a subsidiary of Bonnier News Group AB, has announced a public cash offer of SEK 455 million to the shareholders of Readly International AB (publ).
